AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
🇿🇦
Adalimumab in South Africa
5 products registered with SAHPRA — 4 active
| Brand / Product | Reg. No. | Holder | Status | Expires |
|---|---|---|---|---|
| HYDIMOZ 40 mg/,8 ml | 56/30.1/0665 | Sandoz South Africa (Pty) Ltd | active | 8 Oct 2029 |
| ADALIMUMAB 40 mg/0,8 ml FRESENIUS | 55/30.2/0285 | Fresenius Kabi South Africa (Pty) Ltd | active | 11 Jun 2029 |
| RUMIO 40 | 56/36.1/0361 | Cipla Medpro (Pty) Ltd | active | 30 Jan 2029 |
| RUMIO 80 | 56/30.1/0362 | Cipla Medpro (Pty) Ltd | active | 30 Jan 2029 |
| HUMIRA 40 mg | 37/30.2/0252 | Abbvie (Pty) Ltd | suspended | 20 Dec 2021 |
Adalimumab — SAHPRA Registration Details
SAHPRA (South Africa) has 5 registered products containing Adalimumab, of which 4 are currently active. Data is sourced directly from the official SAHPRA drug register and refreshed daily.
Track Adalimumab registration expiry dates, monitor competitor approvals, and receive alerts when registration status changes. Create a free account to set up portfolio monitoring.